GSK (GSK) Stock

GSK PLC's Nucala (mepolizumab) has received approval in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other treatments, such as steroids or surgery, have failed. This approval makes Nucala the first anti-interleukin-5 therapy for this condition in China, where around 30 million people are affected by CRSwNP.

GSK PLC (LSE:GSK, NYSE:GSK) has revealed that its phase III FIRST-ENGOT-OV44 trial achieved its main objective. The research demonstrated that adding Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, greatly enhanced progression-free survival (PFS) in patients with first-line advanced ovarian cancer.

On Friday, GSK announced that their cancer medication Jemperli, when combined with standard chemotherapy and Zejula maintenance, helped patients with advanced ovarian cancer live longer without the disease worsening in a late-stage study.

The CHMP has suggested that GSK's Vocabria and JNJ's Rekambys be approved for marketing to treat HIV-1 infection in teenagers who are 12 years old and above.

GSK PLC (LSE:GSK, NYSE:GSK) has reported important advancements in its cancer treatment development, reaching three key milestones. The European Medicines Agency (EMA) has given a favorable recommendation for the broader use of Jemperli (dostarlimab) combined with chemotherapy as a first-line treatment for advanced or recurring endometrial cancer.

While GSK may not be the top choice among large pharmaceutical companies for your investment portfolio, we think there is a chance for its sales and profits to grow.

Relation has announced two important partnerships with GSK to develop treatments for fibrotic diseases and osteoarthritis. These collaborations will work on finding and confirming new therapeutic targets for these conditions. The announcement was made in London on December 10, 2024.

On Monday afternoon, GSK PLC's shares in New York increased after the company revealed that its blood cancer medication, Blenrep (belantamab mafodotin), greatly improved survival rates in an important trial. When used with two other treatments, the drug lowered the risk of death by 42% compared to a competing product from Johnson & Johnson, as shown in results shared at the American Society of Hematology's annual meeting.

On Monday, British pharmaceutical company GSK announced that its trial cancer drug Blenrep, when used with other therapies, lowered the risk of death by 42% in patients with multiple myeloma, a frequent form of blood cancer, after their first relapse compared to a current treatment.